Christopher Leidli Email & Phone Number

Wilmington, DE, US

We are building software and data solutions to help accelerate patient access to advanced medicines, including cell therapies, gene therapies, biologics, and radiopharmaceuticals.

I help Life Science companies prepare for launch and commercialization with a focus on advanced therapies, including Precision Medicines, Biologics, Antibody Drug Conjugates (ADCs) and Cell and Gene Therapies.

Responsible for crafting and executing the advanced medicines vision and growth stratey for Verascity Science, a leading medical communications agency. I support medical communications, marketing, digital, social media, market access, and commercialization strategy across all Brightly Network agencies (BluPrint Oncology, Blendworks). In this role, I help.

San Carlos, California, US

At Iovance, I led the commercial launch readiness for the first T cell therapy to treat solid tumors. Developed the marketing plan working across clinical development, manufacturing, and commercial functions to potentially lead to the first Tumor Infiltrating Lymphocyte (TIL) FDA filing in history. Served as the primary point of contact for developing and.

Boulder, CO, US

At Array BioPharma, I was responsible for all aspects of U.S. Commercial Launch, HCP and Payer Marketing of BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) targeted therapy combination for patients with BRAF-mutant metastatic melanoma. Achieved over $135M in U.S. net sales within first 12 months of launch; demand significantly exceeded forecasts. Advanced.

Leverkusen, North Rhine-Westphalia, DE

I led the WW launch of STIVARGA [regorafenib], a molecular targeted therapy, that was behind-schedule and successfully aligned the global cross-functional team on commercialization strategy; delivered $250M in sales within first year of approval.

Paris, France, FR

Deployed successful marketing campaigns and owned their implementation from ideation to execution. Built strategic relationships and partnered with key industry players, agencies, and vendors.Developed and negotiated novel contracting strategies for multibillion dollar Oncology portfolio in highly competitive, Medicare Part B buy-and-bill market.Built.

Paris, France, FR

Paris, France, FR

New Brunswick, NJ, US

Crafted Oncology Therapeutic Area Strategy and provided commercial input for hematology and solid tumor portfolio resulting in the funding and advancement of two new pipeline programs.Evaluated the commercial potential of 5 novel pipeline assets, in the oncology space, using market analysis and financial modeling, to support in-licensing and business.

Rockville, MD, US

Developed clinical development and commercial plans for genomics-derived products targeting lymphoma and other B-cell malignancies.Led a cross-functional team of medical experts and genome data scientists to develop valuation models using NPV to analyze commercial potential of pipeline products.

Thousand Oaks, CA, US

Led immunology and cancer biology research team in genomic and proteomic analysis to identify targets for therapeutic intervention with biologics, including engineered proteins and neutralizing antibodies. Worked with process development to support scale up and analytical validation utilizing multiplexed cell-based assays and flow cytometry to characterize.

Mba, Marketing, Health Care Policy

Ms, Molecular Physiology And Pharmacology

Ba, Biopsychology

High School Diploma, College/University Preparatory And Advanced High School/Secondary Diploma Program